Is Uric Acid an Underdiagnosed Mediator of Adverse Outcome in Metabolically Healthy Overweight/Obese Individuals? - 22/05/14
Doi : 10.1016/j.amjmed.2014.02.031
Mehdi A. Fini, MD a, b, Richard M. Wright, PhD a, b, c, Kurt R. Stenmark, MD b, d, Stephen R. Daniels, MD, PhD d, Richard J. Johnson, MD a, e
a Department of Medicine, University of Colorado Denver, School of Medicine, Aurora
b Division of Pulmonary and Critical Care, University of Colorado Denver, School of Medicine, Aurora
c Webb-Waring Center, University of Colorado Denver, School of Medicine, Aurora
d Department of Pediatrics, University of Colorado Denver, School of Medicine, Aurora
e Division of Renal Diseases and Hypertension, University of Colorado Denver, School of Medicine, Aurora
Le texte complet de cet article est disponible en PDF.
| Funding: National Institutes of Health HL113809 and HL007171. |
|
| Conflict of Interest: RJJ holds patent applications related to decreasing uric acid in the treatment of metabolic syndrome, kidney disease, and hypertension, and has consulted for Ardea, Novartis, Danone, and Astellas. He also holds a patent for the use of allopurinol to treat primary hypertension with the University of Washington and Merck, Inc. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
© 2014
Elsevier Inc. Tous droits réservés.
Vol 127 - N° 6
P. e21 - juin 2014 Retour au numéro
Article précédent
- Type 2 Myocardial Infarction: The Next Frontier
- Yader Sandoval, Stephen W. Smith, Fred S. Apple
- Antibiotic Therapy for Appendicitis in Patients Aged ?80 Years
- Hyoung-Chul Park, Min Jeong Kim, Bong Hwa Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?